Compare Edison International Common Stock (EIX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edison International Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Edison International Common Stock trades at $55.7 (market cap $21.35B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Edison International Common Stock is far larger — about 2.9× Spyre Therapeutics Inc. Common Stock's market cap, and Edison International Common Stock pays a 6.33% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 4 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EIX | SYRE | |
|---|---|---|
Market Cap | $21.35B | $7.35B |
Volume | 15,485,731 | 1,624,631 |
Sector | Utilities | Health |
52-Week High | $80.38 | $108.92 |
52-Week Low | $51.47 | $22.18 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $64.73B | $6.35B |
Dividend Yield | 6.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edison International (EIX) trades at $55.48, down 0.29% on the day, with a bullish technical signal despite mixed oscillators. The stock offers a high dividend yield of 6.4% and trades below the consensus price target of $59.29. Recent earnings have consistently beaten estimates, with Q3 2026 results pending. However, the stock faces headwinds from unresolved California wildfire liability risks, contributing to a 23% decline in late August 2026.
EIX presents a value opportunity with low P/E (5.73) and P/B (1.22) ratios, strong profitability (ROE 23.06%), and a stable dividend. Key risks include regulatory uncertainty around wildfire costs and a projected decline in 2026 net margin. Analyst sentiment is mixed but leans positive, with 40.5% buy ratings. The stock's upside depends on regulatory clarity and sustained earnings growth.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edison International Common Stock
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
